OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. De Censi on the Hope for Biosimilars in the United States

September 13th 2019

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.

Dr. Siddiqi on the Safety Profile of Liso-Cel in the TRANSCEND CLL 004 Trial

September 13th 2019

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the safety profile of lisocabtagene maraleucel (liso-cel; JCAR017) in the TRANSCEND CLL 004 trial.

Dr. Denduluri on the Role of Neoadjuvant Therapy in HER2+ Breast Cancer

September 12th 2019

Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses the role of neoadjuvant therapy in HER2-positive breast cancer and triple-negative breast cancer.

Dr. Voorhees on the ELOQUENT-3 Trial in Late Relapsed/Refractory Multiple Myeloma

September 12th 2019

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.

Dr. Lieu Discusses the Focus of Future Research in mCRC

September 12th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.

Dr. Rosen on the Emergence of Novel Therapies and Research With IO in Hematologic Malignancies

September 12th 2019

Steven T. Rosen, MD, Irell & Manella Cancer Center Director's Distinguished Chair, Morgan & Helen Chu Director's Chair of the Beckman Research Institute, provost and chief scientific officer, director of the Comprehensive Cancer Center, Beckman Research Institute, and Irell & Manella Graduate School of Biological Sciences, and professor in the Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope, discusses the emergence of novel therapies and the incorporation of immuno-oncology (IO) drugs in hematologic malignancies.

Dr. Lyman on Educational Initiatives Regarding the Use of Biosimilars in Oncology

September 12th 2019

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses educational initiatives regarding the use of biosimilars in oncology.

Dr. Smith on Emerging Therapies in Indolent Lymphoma

September 11th 2019

Mitchell R. Smith, MD, PhD, professor of medicine, George Washington University, associate center director for clinical investigations, Division of Hematology and Oncology, GW Cancer Center, discusses emerging therapeutic approaches in indolent lymphoma.

Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma

September 11th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab and the PD-1 inhibitor nivolumab, in melanoma.

Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCC

September 11th 2019

Toni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.

Dr. Martin Discusses the Heterogeneity of MCL

September 11th 2019

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses the heterogeneity of mantle cell lymphoma (MCL).

Dr. Kohli Discusses Ongoing Correlative Science in Prostate Cancer

September 11th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses ongoing research with correlative sciences in prostate cancer.

Dr. Krishnan on Key Aspects of the ELOQUENT Trials in Relapsed/Refractory Multiple Myeloma

September 11th 2019

Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and a professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses key aspects of the phase III ELOQUENT-2 and -3 trials in relapsed/refractory multiple myeloma.

Dr. Yadav on the Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma

September 10th 2019

Ghanshyam Yadav, MD, discusses research surrounding the combination of the PARP inhibitor olaparib and the pan-HER TKI neratinib, which proved to be highly synergistic and had significant activity in preclinical models of HER2-positive uterine serous carcinoma.

Dr. Gupta on Enzalutamide/Chemo Combo in Metastatic Bladder Cancer

September 10th 2019

Shilpa Gupta, MD, associate professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the results of the phase I/Ib trial investigating the use of frontline enzalutamide, gemcitabine and cisplatin in metastatic bladder cancer.

Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer

September 10th 2019

Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Marks on PHENIX Trial Data in HER2+ Breast Cancer

September 10th 2019

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

Dr. Ghia on ASCEND Trial Results for Previously Treated CLL

September 10th 2019

Paolo Ghia, MD, discusses the efficacy results of the ASCEND trial, which examined the use of acalabrutinib monotherapy in patients with previously treated chronic lymphocytic leukemia.

Dr. Sonpavde on Immunotherapy After Progression in Advanced Bladder Cancer

September 10th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Dr. Henderson on Anticipated Developments With Radiotherapy in Prostate Cancer

September 10th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses anticipated developments with radiotherapy in prostate cancer.